Bevacizumab biosimilar - Mabion
Alternative Names: MabionVEGFLatest Information Update: 12 Jan 2022
Price :
$50 *
At a glance
- Originator Mabion
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Endothelial growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Cancer in Poland
- 05 May 2015 Early research in Cancer in Poland (unspecified route)